- Saudi Arabia lauds Pakistan Army’s role in regional peace RADIO PAKISTAN
- Field Marshal Munir expresses satisfaction with ‘robust defence collaboration’ in meeting with Saudi military commander Dawn
- The Role of Status in the Pak-Saudi…
Author: admin
-
Saudi Arabia lauds Pakistan Army’s role in regional peace – RADIO PAKISTAN
-

Reassessing Valuation After New NexusWave Upgrades and Azerbaijan Airlines Wi‑Fi Deal
Viasat (VSAT) is back in focus after a one two punch of product momentum and new client wins, from upgraded NexusWave maritime connectivity to a fresh in flight Wi Fi deal with Azerbaijan Airlines.
See our latest analysis for Viasat.
Those connectivity wins come after a volatile stretch for the stock, with a roughly 252 percent year to date share price return and a 263 percent one year total shareholder return, suggesting momentum is very much rebuilding around the Viasat story.
If you like how Viasat is repositioning around connectivity demand, it could be worth scanning high growth tech and AI stocks for other tech names riding similar structural growth trends.
With the shares up more than 250 percent this year but still trading at a steep intrinsic discount and only a modest gap to Wall Street targets, is Viasat a mispriced turnaround, or is the market already banking on years of growth?
With Viasat closing at $33.57 against a narrative fair value of $36.25, the implied upside leans modestly positive, hinging on improving profitability and capital discipline.
The focus on operational efficiency, portfolio review, and progressing integration with Inmarsat, in addition to CapEx peaking with the ViaSat-3 program, sets up Viasat for positive free cash flow inflection, deleveraging, and earnings improvement as major investment cycles wind down. Rising government and commercial interest in bridging the digital divide, especially in underserved and remote areas, provides a multi-year tailwind through subsidy programs and public/private contracts, supporting stable, recurring revenue streams and margin visibility.
Read the complete narrative.
Want to see the math behind that upside call? The narrative leans on slower but steady revenue gains, sharply better margins, and a future earnings multiple that might surprise you.
Result: Fair Value of $36.25 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, execution risk around ViaSat-3 spending and intensifying competition from Starlink and Project Kuiper could quickly undermine the turnaround narrative that investors are embracing.
Find out about the key risks to this Viasat narrative.
If this take does not quite match your view, or you would rather dig into the numbers yourself, you can build a custom storyline in just a few minutes, starting with Do it your way.
A great starting point for your Viasat research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
Continue Reading
-
Bilawal Bhutto inaugurates dialysis, lithotripsy centers at SIUT Karachi – RADIO PAKISTAN
- Bilawal Bhutto inaugurates dialysis, lithotripsy centers at SIUT Karachi RADIO PAKISTAN
- Bilawal opens two SIUT units at hospital’s new building Dawn
- SIUT opens new dialysis, lithotripsy centre in Karachi The Express Tribune
- Bilawal Bhutto calls…
Continue Reading
-

PAHO Urges Stronger Health Laws in the Caribbean
The bustling capital of Santo Domingo served as the backdrop for a pivotal moment in regional health policy this December. Dr. Jarbas Barbosa, the Director of the Pan American Health Organization, arrived in the Dominican…
Continue Reading
-

Mohit Sharma retires from all formats of cricket
“A very special thank you to the Haryana Cricket Association for being the backbone of my career. And my deepest gratitude to Anirudh Sir, who’s constant guidance and belief in me shaped my path in ways words cannot express. Thank you to the…
Continue Reading
-
Participation in commercial clinical trials falls for fourth year in a row, finds ABPI – The Pharmaceutical Journal
- Participation in commercial clinical trials falls for fourth year in a row, finds ABPI The Pharmaceutical Journal
- Decline in commercial clinical trial recruitment selling patients short, says ABPI Association of the British Pharmaceutical Industry (ABPI)
- New IP guidance for the NHS Burges Salmon
- Slow recruitment still hitting UK trials, says pharma pharmaphorum
- UK patients being “denied access to cutting-edge clinical research” Clinical Trials Arena
Continue Reading
-

Aluminum Adjuvant Imject Alum Drives Liver Fibrosis in Novel Mouse Model
Researchers in China have developed a novel mouse model of liver fibrosis using a widely used aluminum-based vaccine adjuvant, potentially offering a new platform to study immune-mediated liver injury and test antifibrotic therapies.
In the…
Continue Reading
-

‘It was legs out all the time!’ June Squibb on starring in Scarlett Johansson’s directing debut – and Broadway’s original Gypsy | Film
It is surely a comfort to anyone still awaiting mega-success to know that June Squibb was in her mid-80s before she hit the big time. Her role as a foul-mouthed matriarch in the 2013 film Nebraska brought her an Oscar nomination, and she had her…
Continue Reading
-

Check Point Software Technologies Named a Leader in Gartner Magic Quadrant for Email Security
Check Point® Software Technologies Ltd. (NASDAQ: CHKP), a pioneer and global leader of cyber security solutions, announces that it has been recognized as a Leader in the 2025 Gartner® Magic Quadrant™ for Email Security. Excelling across key…
Continue Reading
-

Homo sapiens-specific evolution unveiled by ancient southern African genomes
Nielsen, R. et al. Tracing the peopling of the world through genomics. Nature 541, 302–310 (2017).
Google Scholar
Hublin, J.-J. et al. New…
Continue Reading